Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease

Core Insights - Jupiter Neurosciences, Inc. has received FDA clearance for its Investigational New Drug application to initiate a Phase 2a clinical trial of JOTROL for Parkinson's disease [1][2][3] - The Phase 2a trial aims to evaluate the safety and tolerability of JOTROL, with additional endpoints to assess pharmacokinetics and pharmacodynamics [2][3] - JOTROL has shown strong safety and bioavailability in Phase I studies, with preclinical evidence suggesting potential neuroprotective benefits [3][4] Company Overview - Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on neuroinflammation and healthy aging, with a therapeutic pipeline targeting CNS disorders and rare diseases [6] - The company is advancing JOTROL, a proprietary resveratrol formulation, which has demonstrated over nine-fold higher bioavailability compared to traditional resveratrol [4][8] - Jupiter is also expanding into the consumer longevity market with its Nugevia product line, which leverages the same delivery technology as JOTROL [6][9] Market Context - Parkinson's disease affects over 10 million people globally, with no current disease-modifying treatments available, highlighting a significant unmet medical need [5] - The global market for Parkinson's therapeutics is projected to exceed $14 billion by 2030, indicating a strong demand for innovative treatments [5]